Mafusol and its combination with REXOD as correctors of reduced blood circulation in the skin associated with normoglycemia or diabetes mellitus complicated by exogenous hypercholesterolemia

Abstract

Introduction: The search for and development of new highly active medications and their combinations of the appropriate direction of action remains an urgent problem due to the complications of diabetes mellitus, especially burdened with atherosclerosis, including skin and vascular lesions. Materials and methods: The acute toxicity, histoprotective and dermatoprotective effects of mafusol, rexod, alprostadil and their combinations were studied in male rats with normoglycemia and alloxan diabetes complicated by exogenous hypercholesterolemia. Results: The combination of mafusol with rexod is less toxic than mafusol. In arteriovenous insufficiency of the tail, ischemia of the skin fold and skin flap, mafusol (6.25, 12.5 and 25.0 mg/kg in terms of fumarate), rexod (0.01 and 0.02 mg/kg) and especially their combination (6.25 and 0.01 mg/kg) have significant histoprotective, dermatoprotective, hypoglycemic and lipid-lowering effects, both in normoglycemia and alloxan diabetes complicated by exogenous hypercholesterolemia. Alprostadil (10 mg/kg) and especially its combination with mafusol (6.25 mg/kg) have a dermatoprotective effect. Discussion: Rexod reduces the acute toxicity of mafusol. The dermatoprotective effect of mafusol, rexod and, to a greater extent, their combination may be associated with increased microhemocirculation, antihypoxic properties and activation of energy processes in the skin, normalization of carbohydrate and lipid metabolism in alloxan diabetes, complicated by exogenous hypercholesterolemia, increased reserve capacity of the antioxidant system, and possibly with the ability of mafusol and rexod to reduce blood viscosity and improve rheological properties of the blood. The combination of mafusol with alprostadil increases the dermatoprotective activity of the latter. Conclusion: Combinations of mafusol with rexod and alprostadil can be recommended for clinical study as dermatoprotective agents for treating traumatic injuries and diabetes mellitus complicated by atherosclerosis.

The effect of the composition of Soderm®-Forte gel and the new injectable form of Rexod® on pathology findings in gingival tissue in experimental periodontitis in rats

“…At the level of periodontal tissues, this is manifested by disorders of oxidative homeostasis, impaired functions of the endothelial system and peripheral microcirculation, as well as an increase in vascular-tissue permeability (Chen et al 2019), which ultimately leads to the development of morphofunctional disorders in the periodontal complex. Among the agents capable of significantly reduce the harmful effects of FR, in particular reactive oxygen species and lipid peroxidation, an important place is given to recombinant human superoxide dismutase (SOD) -Rexod ® , especially its new injectable form (NIF) -NIF of Rexod ® (Gulevskaya et al 2021).…”